WG
MCID: WGN006
MIFTS: 63

Wegener Granulomatosis (WG) malady

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Immune diseases

Aliases & Classifications for Wegener Granulomatosis

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 30ICD10, 31ICD10 via Orphanet, 32ICD9CM, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Wegener Granulomatosis:

Name: Wegener Granulomatosis 52 11 48 25 54 12
Granulomatosis with Polyangiitis 48 25 54 38 39 68
Wegener's Granulomatosis 11 25 13
Gpa 48 25 54
Midline Granulomatosis 48 68
Pauci-Immune Glomerulonephritis Associated with Granulomatosis with Polyangiitis 68
 
Necrotizing Respiratory Granulomatosis 11
Granulomatosis - Wegener's 11
Wegeners Granulomatosis 50
Wegener's Syndrome 11
Wg 48

Characteristics:

Orphanet epidemiological data:

54
granulomatosis with polyangiitis:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-5/10000 (Sweden),1-9/1000000 (Germany),1-9/100000 (France),1-9/100000 (Sweden),1-9/100000 (Norway),1-9/100000 (Australia),1-9/100000 (New Zealand),1-9/100000 (United States),1-9/100000 (China),1-9/1000000 (Lithuania),1-9/1000000 (Greece),1-9/1000000 (Italy),1-9/1000000 (Canada),1-9/1000000 (Japan),<1/1000000 (Taiwan, Province of China),1-9/100000 (Italy),1-5/10000 (Denmark); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

OMIM52 608710
Disease Ontology11 DOID:12132
ICD1030 M31.3, M31.30
ICD9CM32 446.4
MeSH39 D014890
NCIt45 C3444
Orphanet54 ORPHA900
MESH via Orphanet40 D014890
UMLS via Orphanet69 C0043092
ICD10 via Orphanet31 M31.3

Summaries for Wegener Granulomatosis

About this section
MedlinePlus:38 Granulomatosis with polyangiitis (gpa), previously known as wegener's granulomatosis, is a rare disease. it is a type of vasculitis, or inflammation of the blood vessels. the inflammation limits the flow of blood to important organs, causing damage. it can affect any organ, but it mainly affects the sinuses, nose, trachea (windpipe), lungs, and kidneys. the cause of gpa is unknown. it can affect people at any age. men and women are equally affected. it is more common in whites. symptoms may include joint pain, weakness, tiredness, and cold symptoms such as a runny nose that doesn't get better. doctors use blood tests, chest x-rays, and biopsies to diagnose gpa and rule out other causes of the symptoms. early treatment is important. most people improve with medicines to slow or stop the inflammation. nih: national institute of allergy and infectious diseases

MalaCards based summary: Wegener Granulomatosis, also known as granulomatosis with polyangiitis, is related to labyrinthitis and choroiditis, and has symptoms including angina pectoris, chest pain and coughing. An important gene associated with Wegener Granulomatosis is WG (Wegener Granulomatosis), and among its related pathways are C-MYB transcription factor network and amb2 Integrin signaling. The drug cyclophosphamide has been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and skin, and related mouse phenotypes are cardiovascular system and hematopoietic system.

Disease Ontology:11 An autoimmune disease that is located in lung, located in kidney, located in skin resulting from an autoimmune attack by antineutrophil cytoplasmic antibodies against small and medium-size blood vessels.

Genetics Home Reference:25 Granulomatosis with polyangiitis (GPA) is a condition that causes inflammation that primarily affects the respiratory tract (including the lungs and airways) and the kidneys. This disorder is also commonly known as Wegener granulomatosis. A characteristic feature of GPA is inflammation of blood vessels (vasculitis), particularly the small- and medium-sized blood vessels in the lungs, nose, sinuses, windpipe, and kidneys, although vessels in any organ can be involved. Polyangiitis refers to the inflammation of multiple types of vessels, such as small arteries and veins. Vasculitis causes scarring and tissue death in the vessels and impedes blood flow to tissues and organs.

NIH Rare Diseases:48 Granulomatosis with polyangiitis (wegener's) is a type of vasculitis, or inflammation of the blood vessels. this limits the flow of blood to important organs, causing damage. it can affect any organ, but it mainly affects the sinuses, nose, trachea (windpipe), lungs and kidneys. symptoms can vary in nature and severity, and may include sinus pain; discolored or bloody fluid from the nose; nasal ulcers; constant runny nose (rhinorrhea); joint pain; weakness; tiredness; and/or skin lesions. the cause of granulomatosis with polyangiitis is unknown. early treatment is important. most people improve with medicines to slow or stop the inflammation. last updated: 5/25/2015

OMIM:52 Wegener granulomatosis (WG) is a systemic disease with a complex genetic background. It is characterized by necrotizing... (608710) more...

Wikipedia:71 Granulomatosis with polyangiitis (GPA), previously known as Wegener\'s granulomatosis (WG), is a... more...

Related Diseases for Wegener Granulomatosis

About this section

Diseases related to Wegener Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 229)
idRelated DiseaseScoreTop Affiliating Genes
1labyrinthitis29.9CXCL8, IL10, TNF
2choroiditis29.9CRP, CXCL8, IL10, TNF
3blue toe syndrome29.8CXCL8, IFNG, IL10, TNF
4pyoderma gangrenosum29.4CXCL8, IFNG, TNF
5goodpasture syndrome29.4CCR5, CRP, CTLA4, CXCL8, IFNG, IL10
6rheumatoid arthritis29.4CRP, CTLA4, CXCL8, HLA-DPB1, IFNG, IL10
7eosinophilic granulomatosis with polyangiitis12.5
8anca-associated vasculitis11.5
9pyridoxal 5'-phosphate-dependent epilepsy10.4IL10, TNF
10autosomal dominant charcot-marie-tooth disease type 2 with giant axons10.4MPO, TNF
11villous adenoma10.4CRP, MPO, PRTN3
12hypolipoproteinemia10.4CRP, MPO, PRTN3
13scalp dermatosis10.4CRP, MPO, TNF
14hirschsprung disease 710.4ELANE, PRTN3, SELE
15tubular renal disease-cardiomyopathy syndrome10.4IL10, TNF
16severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive10.4IFNG, IL10, TNF
17distal trisomy 14q10.4HLA-DPB1, IFNG, TNF
18elephantiasis10.4IFNG, IL10, PRTN3
19urticaria10.4CRP, MPO, TNF
20dancing eyes-dancing feet syndrome10.4ELANE, ELN, MPO
21cyclosporiasis10.4IFNG, IL10, TNF
22subacute glomerulonephritis10.4CRP, ELANE, MPO, PRTN3
23neurotic disorder10.4IFNG, IL10, TNF
24hypertropia10.4CRP, IFNG, TNF
25astrocytoma10.4IL10, MPO, PRTN3, TNF
26pericholangitis10.4CRP, MPO, TNF
27low anorectal malformation10.4CTLA4, IL10, TNF
28tetanus10.4ELANE, ELN, TNF
29conduct disorder10.4IFNG, IL10, TNF
30pancreatic signet ring cell adenocarcinoma10.4IFNG, IL10, TNF
31pulpitis10.4IFNG, IL10, TNF
32tularemia10.4IFNG, IL10, TNF
33urethral intrinsic sphincter deficiency10.4IFNG, SELE, TNF
34ectodermal dysplasia bartalos type10.4IFNG, IL10, TNF
35conidiobolomycosis10.4CXCL8, IL10, TNF
36multiple mitochondrial dysfunctions syndrome10.4CRP, IFNG, IL10
37hereditary alpha tryptasemia syndrome10.3IFNG, IL10, TNF
38rickettsialpox10.3IFNG, IL10, TNF
39acute myeloid leukemia with recurrent genetic anomaly10.3IFNG, IL10, TNF
40myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr110.3CCR5, IFNG, TNF
41angiomatosis, diffuse corticomeningeal, of divry and van bogaert10.3CTLA4, MPO, SERPINA1, TNF
42cardiomyopathy diabetes deafness10.3CRP, CXCL8, ELANE
43t-cell prolymphocytic leukemia10.3CCR5, PTPN22, TNF
44microcephaly10.3IFNG, IL10, TNF
45omsk hemorrhagic fever10.3CXCL8, ELANE, MPO
46radial hypoplasia, triphalangeal thumbs and hypospadias10.3ELANE, SELE, TNF
47benign secondary hypertension10.3CCR5, CTSG, MPO
48rosacea10.3IFNG, IL10, SELE
49esotropia10.3CRP, MPO, PRTN3, SELE
50cicatricial lagophthalmos10.3CRP, CXCL8, TNF

Comorbidity relations with Wegener Granulomatosis via Phenotypic Disease Network (PDN):


Deficiency AnemiaAcute Kidney Failure
Chronic Kidney FailureNeutropenia
Respiratory Failure

Graphical network of the top 20 diseases related to Wegener Granulomatosis:



Diseases related to wegener granulomatosis

Symptoms & Phenotypes for Wegener Granulomatosis

About this section


Clinical features from OMIM:

608710

Human phenotypes related to Wegener Granulomatosis:

 54 64 (show all 67)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 prostatitis64 54 Occasional (29-5%) HP:0000024
2 ureteral stenosis64 54 Occasional (29-5%) HP:0000071
3 renal insufficiency64 54 Occasional (29-5%) HP:0000083
4 proteinuria64 54 Frequent (79-30%) HP:0000093
5 hydronephrosis64 54 Occasional (29-5%) HP:0000126
6 abnormality of the oral cavity64 54 Very frequent (99-80%) HP:0000163
7 sinusitis64 54 Very frequent (99-80%) HP:0000246
8 abnormality of the nose54 Very frequent (99-80%)
9 otitis media54 Very frequent (99-80%)
10 chronic otitis media64 54 Occasional (29-5%) HP:0000389
11 sensorineural hearing impairment64 54 Occasional (29-5%) HP:0000407
12 epistaxis64 54 Very frequent (99-80%) HP:0000421
13 retinopathy64 54 Occasional (29-5%) HP:0000488
14 visual impairment64 54 Occasional (29-5%) HP:0000505
15 proptosis64 54 Occasional (29-5%) HP:0000520
16 sensory neuropathy64 54 Occasional (29-5%) HP:0000763
17 hematuria64 54 Very frequent (99-80%) HP:0000790
18 hypertension64 54 Occasional (29-5%) HP:0000822
19 abnormality of the hypothalamus-pituitary axis64 54 Frequent (79-30%) HP:0000864
20 diabetes insipidus64 54 Occasional (29-5%) HP:0000873
21 purpura64 54 Occasional (29-5%) HP:0000979
22 skin rash64 54 Frequent (79-30%) HP:0000988
23 seizures64 54 Occasional (29-5%) HP:0001250
24 meningitis64 54 Occasional (29-5%) HP:0001287
25 angina pectoris64 54 Occasional (29-5%) HP:0001681
26 pericarditis64 54 Occasional (29-5%) HP:0001701
27 pancreatitis64 54 Occasional (29-5%) HP:0001733
28 weight loss64 54 Very frequent (99-80%) HP:0001824
29 fever64 54 Very frequent (99-80%) HP:0001945
30 nausea and vomiting64 54 Frequent (79-30%) HP:0002017
31 abdominal pain64 54 Frequent (79-30%) HP:0002027
32 restrictive lung disease54 Occasional (29-5%)
33 respiratory insufficiency64 54 Frequent (79-30%) HP:0002093
34 pleuritis64 54 Occasional (29-5%) HP:0002102
35 hemoptysis64 54 Frequent (79-30%) HP:0002105
36 pulmonary infiltrates64 54 Very frequent (99-80%) HP:0002113
37 recurrent respiratory infections64 54 Very frequent (99-80%) HP:0002205
38 pulmonary fibrosis64 54 Frequent (79-30%) HP:0002206
39 gastrointestinal hemorrhage64 54 Occasional (29-5%) HP:0002239
40 hemiplegia64 54 Occasional (29-5%) HP:0002301
41 headache64 54 Occasional (29-5%) HP:0002315
42 vasculitis64 54 Very frequent (99-80%) HP:0002633
43 cerebral ischemia64 54 Very frequent (99-80%) HP:0002637
44 arthralgia64 54 Very frequent (99-80%) HP:0002829
45 granulomatosis64 54 Very frequent (99-80%) HP:0002955
46 autoimmunity64 54 Very frequent (99-80%) HP:0002960
47 myalgia64 54 Occasional (29-5%) HP:0003326
48 elevated erythrocyte sedimentation rate64 54 Frequent (79-30%) HP:0003565
49 venous thrombosis64 54 Occasional (29-5%) HP:0004936
50 intestinal obstruction64 54 Occasional (29-5%) HP:0005214
51 chronic obstructive pulmonary disease64 54 Frequent (79-30%) HP:0006510
52 recurrent intrapulmonary hemorrhage64 54 Frequent (79-30%) HP:0006535
53 cranial nerve paralysis64 54 Occasional (29-5%) HP:0006824
54 peripheral neuropathy54 Frequent (79-30%)
55 elevated c-reactive protein level64 54 Frequent (79-30%) HP:0011227
56 arrhythmia64 54 Occasional (29-5%) HP:0011675
57 fatigue64 54 Very frequent (99-80%) HP:0012378
58 increased inflammatory response54 Frequent (79-30%)
59 cough64 54 Frequent (79-30%) HP:0012735
60 inflammatory abnormality of the eye64 54 Frequent (79-30%) HP:0100533
61 periorbital edema64 54 Frequent (79-30%) HP:0100539
62 chest pain64 54 Frequent (79-30%) HP:0100749
63 gangrene64 54 Occasional (29-5%) HP:0100758
64 glomerulopathy64 54 Very frequent (99-80%) HP:0100820
65 papule64 54 Frequent (79-30%) HP:0200034
66 skin ulcer64 54 Occasional (29-5%) HP:0200042
67 restrictive ventilatory defect64 HP:0002091

UMLS symptoms related to Wegener Granulomatosis:


angina pectoris, chest pain, coughing, edema, snoring

MGI Mouse Phenotypes related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053859.5CCR5, CRP, CTLA4, IFNG, IL10, MPO
2MP:00053979.0CCR5, CD177, CTLA4, CTSG, ELANE, IFNG
3MP:00053708.8CCR5, CTLA4, CTSG, IFNG, IL10, PTPN22
4MP:00053878.8CCR5, CD177, CRP, CTLA4, CTSG, ELANE

Drugs & Therapeutics for Wegener Granulomatosis

About this section

Drugs for Wegener Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 108)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Methylprednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3119383-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
2
Mycophenolate mofetilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
3
Prednisoloneapproved, vet_approvedPhase 4, Phase 2, Phase 3119350-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
 
MLS001304083
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
4
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
Mycophenolic acidapprovedPhase 4, Phase 3, Phase 2, Phase 195224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
6
AzathioprineapprovedPhase 4, Phase 3, Phase 2177446-86-62265
Synonyms:
446-86-6
55774-33-9 (hydrochloride salt)
6-((1-Methyl-4-nitro-1H-imidazol-5-yl)thio)-1H-purine
6-((1-Methyl-4-nitroimidazol-5-yl)thio)purine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)-mercaptopurine
6-(1'-Methyl-4'-nitro-5'-imidazolyl)mercaptopurine
6-(1-Methyl-4-nitroimidazol-5-yl)thiopurine
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin
6-(1-Methyl-4-nitroimidazol-5-ylthio)purin [Czech]
6-(1-Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(1-Methyl-p-nitro-5-imidazolyl)thiopurine
6-(3-Methyl-5-nitro-3H-imidazol-4-ylsulfanyl)-7H-purine
6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purine
6-(Methyl-p-nitro-5-imidazolyl)-thiopurine
6-(Methyl-p-nitro-5-imidazolyl)thiopurine
6-({4-nitro-1-methyl-1H-imidazol-5-yl}sulfanyl)-7H-purine
6-1'-Methyl,4'-nitro,5'-imidazolyl mercaptopurine
6-[(1-Methyl-4-nitroimidazol-5-yl)- thio] purine
6-[(1-Methyl-4-nitroimidazol-5-yl)thio]purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)sulfanyl]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-Purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine
6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purine
A 4638
A2593_SIAL
A4638_SIAL
A4638_SIGMA
AB00443544
AB00443544-03
AC-4230
AC1L1DAL
AC1Q3Z1F
AI-981/34845012
AI3-50290
Azamun
Azamun [Czech]
Azanin
Azasan
Azasan (TN)
Azasan, Imuran, Azamun, BW-57-322, NSC-39084, Azathioprine
Azathioprin
Azathioprine (JP15/USP/INN)
Azathioprine Sodium
Azathioprine [USAN:INN:BAN:JAN]
Azathioprine sodium
Azathioprinum
Azathioprinum [INN-Latin]
Azathiopurine
Azatioprin
Azatioprina
Azatioprina [INN-Spanish]
Azothioprine
B. W. 57-322
BPBio1_000054
BRD-K32821942-001-05-6
BRD-K60324116-001-01-5
BSPBio_000048
BSPBio_001876
BW 57-322
BW 57322
BW-57-322
C06837
C9H7N7O2S
CAS-446-86-6
CBDivE_013132
CCRIS 62
CHEBI:2948
CHEMBL1542
CID2265
CPD000427366
Ccucol
ChemDiv1_002659
Cytostatics
D00238
DB00993
DivK1c_000586
EINECS 207-175-4
EU-0100027
FT-0083532
HMS1568C10
HMS1920E17
 
HMS2091K19
HMS501N08
HMS594I19
HSDB 7084
IDI1_000586
Immuran
Imuran
Imuran (TN)
Imuran (tn)
Imurek
Imurel
KBio1_000586
KBio2_000464
KBio2_002427
KBio2_003032
KBio2_004995
KBio2_005600
KBio2_007563
KBio3_001376
KBio3_002906
KBioGR_000646
KBioGR_002427
KBioSS_000464
KBioSS_002433
LS-123
Lopac-A-4638
Lopac0_000027
MLS001049307
Methylnitroimidazolylmercaptopurine
MolPort-000-745-914
MolPort-000-764-262
MolPort-003-665-485
Muran
NCGC00015060-01
NCGC00015060-02
NCGC00015060-04
NCGC00015060-12
NCGC00090836-01
NCGC00090836-02
NCGC00090836-03
NCGC00090836-04
NCGC00090836-05
NCGC00090836-06
NCGC00094593-01
NCGC00094593-02
NCGC00094593-03
NCI-C03474
NINDS_000586
NSC 39084
NSC-39084
NSC39084
Oprea1_375441
Oprea1_533384
Oprea1_633462
Prestwick0_000094
Prestwick1_000094
Prestwick2_000094
Prestwick3_000094
Prestwick_41
S1721_Selleck
SAM002589938
SDCCGMLS-0065415.P001
SMR000427366
SPBio_000255
SPBio_001987
SPECTRUM1500133
STK831906
STOCK1S-20293
STOCK1S-27186
Spectrum2_000068
Spectrum3_000308
Spectrum4_000243
Spectrum5_000848
Spectrum_000064
Thiopurine 6-(1-methyl-4-nitroimidazol-5-yl)
UNII-MRK240IY2L
WLN: T56 BM DN FN HNJ IS- ET5N CNJ A1 DNW
ZINC04258316
[Methyl(nitroimidazolyl)mercaptopurine]
azathioprine
azatiopr in
cMAP_000046
7
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 115511959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
8
alemtuzumabapproved, investigationalPhase 4310216503-57-0
Synonyms:
Campath
 
MabCampath
alemtuzumab
9
rituximabapprovedPhase 4, Phase 2, Phase 3, Phase 11692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
10
Prednisoneapproved, vet_approvedPhase 4, Phase 2, Phase 3139853-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
 
Juvason
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
11
leucovorinapproved, NutraceuticalPhase 4, Phase 3, Phase 2323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
12
Folic Acidapproved, nutraceutical, vet_approvedPhase 4, Phase 3, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
13Methylprednisolone HemisuccinatePhase 4, Phase 2, Phase 31193
14Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 313168
15Methylprednisolone acetatePhase 4, Phase 2, Phase 31193
16Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 123689
17Prednisolone phosphatePhase 4, Phase 2, Phase 31193
18Protective AgentsPhase 4, Phase 2, Phase 37443
19Vitamin B ComplexPhase 4, Phase 3, Phase 24337
20Prednisolone hemisuccinatePhase 4, Phase 2, Phase 31193
21Prednisolone acetatePhase 4, Phase 2, Phase 31193
22Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 24962
23Hormone AntagonistsPhase 4, Phase 2, Phase 313180
24Neuroprotective AgentsPhase 4, Phase 2, Phase 31716
25HormonesPhase 4, Phase 2, Phase 3, Phase 114415
26ImmunoglobulinsPhase 4, Phase 2, Phase 3, Phase 16394
27Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 113086
28Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 111226
29Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
30Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 110956
31Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17361
32AntibodiesPhase 4, Phase 2, Phase 3, Phase 16394
33Antibodies, Antineutrophil CytoplasmicPhase 4, Phase 3, Phase 211
34AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 112054
35AntiemeticsPhase 4, Phase 2, Phase 34022
36Alkylating AgentsPhase 4, Phase 3, Phase 24827
37Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 110729
38Gastrointestinal AgentsPhase 4, Phase 2, Phase 3, Phase 18402
39glucocorticoidsPhase 4, Phase 2, Phase 35103
40Dermatologic AgentsPhase 4, Phase 3, Phase 25806
41Folic Acid AntagonistsPhase 4, Phase 3, Phase 22257
42Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 35592
43Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 24603
44Autonomic AgentsPhase 4, Phase 2, Phase 310150
45Tin FluoridesPhase 4264
46FolateNutraceuticalPhase 4, Phase 3, Phase 24392
47Vitamin B9NutraceuticalPhase 4, Phase 3, Phase 24392
48Omega 3 Fatty AcidNutraceuticalPhase 41018
49
GemcitabineapprovedPhase 3, Phase 1, Phase 2201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
50
Etanerceptapproved, investigationalPhase 2, Phase 3, Phase 1403185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor

Interventional clinical trials:

(show top 50)    (show all 114)
idNameStatusNCT IDPhase
1Alemtuzumab for ANCA Associated Refractory VasculitisUnknown statusNCT01405807Phase 4
2Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated VasculitisUnknown statusNCT00128895Phase 4
3Treatment of Necrotizing Vasculitides for Patients Older Than 65 YearsCompletedNCT00307671Phase 4
4Rituximab for the Otolaryngologic Manifestations of Granulomatosis With PolyangiitisRecruitingNCT02626845Phase 4
5A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic PolyangitisRecruitingNCT02115997Phase 4
6Low-dose Glucocorticoid Vasculitis Induction StudyRecruitingNCT02198248Phase 4
7Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab DosingRecruitingNCT02749292Phase 4
8Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisActive, not recruitingNCT02169219Phase 4
9Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.Not yet recruitingNCT03164473Phase 4
10Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")TerminatedNCT00747461Phase 4
11Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein LevelsTerminatedNCT00578578Phase 4
12Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)Unknown statusNCT00103792Phase 3
13WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated VasculitidesUnknown statusNCT00349674Phase 3
14Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaUnknown statusNCT00003338Phase 2, Phase 3
15Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaUnknown statusNCT00003337Phase 3
16Etanercept for Wegener's GranulomatosisCompletedNCT00005007Phase 2, Phase 3
17A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02020889Phase 3
18Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)CompletedNCT00647166Phase 3
19Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2, Phase 3
20Belimumab in Remission of VASculitisCompletedNCT01663623Phase 3
21Efficacy Study of Two Treatments in the Remission of VasculitisCompletedNCT00748644Phase 3
22Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated VasculitidesCompletedNCT00430105Phase 2, Phase 3
23Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.CompletedNCT00138983Phase 3
24Rituximab in Eosinophilic Granulomatosis With PolyangiitisRecruitingNCT02807103Phase 3
25Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)RecruitingNCT02108860Phase 3
26The Assessment of Prednisone In Remission Trial - Centers of Excellence ApproachRecruitingNCT01940094Phase 3
27Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)RecruitingNCT02836496Phase 3
28Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell TumoursRecruitingNCT02582697Phase 3
29Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated VasculitisActive, not recruitingNCT00987389Phase 3
30Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated VasculitisActive, not recruitingNCT01731561Phase 3
31Rituximab Vasculitis Maintenance StudyActive, not recruitingNCT01697267Phase 3
32Comparison Between a Long Term and a Conventional Maintenance Treatment With RituximabActive, not recruitingNCT02433522Phase 3
33Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast CancerNot yet recruitingNCT02574455Phase 3
34Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's GranulomatosisTerminatedNCT01446211Phase 3
35Intravenous Immunoglobulin After Relapse in VasculitisTerminatedNCT00307658Phase 3
36Plasma Exchange for Renal VasculitisTerminatedNCT01408836Phase 2, Phase 3
37IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic VasculitisTerminatedNCT00307645Phase 3
38Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic CancerTerminatedNCT01956812Phase 3
39Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing VasculitidesUnknown statusNCT00751517Phase 2
40Improving Outcomes Following Limb Loss: PALS PlusUnknown statusNCT00447655Phase 1, Phase 2
41Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHLUnknown statusNCT01101581Phase 1, Phase 2
42ASIS for Enbrel in Plaque PsoriasisUnknown statusNCT02112097Phase 1, Phase 2
43Phase II Study on Gusperimus in Patients With Refractory Wegener's GranulomatosisCompletedNCT00530075Phase 2
44Daclizumab to Treat Wegener's GranulomatosisCompletedNCT00040248Phase 2
45Abatacept in Treating Adults With Mild Relapsing Wegener's GranulomatosisCompletedNCT00468208Phase 1, Phase 2
46Etanercept to Treat Wegener's GranulomatosisCompletedNCT00001901Phase 2
47Treatment of Wegener's Granulomatosis With CyclophosphamideCompletedNCT00001155Phase 2
48Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis SyndromesCompletedNCT00004567Phase 2
49Steroids and Methotrexate to Treat Systemic VasculitisCompletedNCT00001256Phase 2
50Anti-Cytokine Therapy for VasculitisCompletedNCT00753103Phase 2

Search NIH Clinical Center for Wegener Granulomatosis

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: granulomatosis with polyangiitis

Genetic Tests for Wegener Granulomatosis

About this section

Anatomical Context for Wegener Granulomatosis

About this section

MalaCards organs/tissues related to Wegener Granulomatosis:

36
Lung, Kidney, Skin, Trachea, Neutrophil, Testes, Monocytes

FMA organs/tissues related to Wegener Granulomatosis:

17
Lung, Kidney, Skin

Publications for Wegener Granulomatosis

About this section

Articles related to Wegener Granulomatosis:

(show top 50)    (show all 62)
idTitleAuthorsYear
1
Sinonasal imaging findings in granulomatosis with polyangiitis (Wegener granulomatosis): A systematic review. (28234146)
2017
2
Granulomatosis with polyangiitis (Wegener granulomatosis): a proteinase-3 driven disease? (28495524)
2017
3
Granulomatosis with Polyangiitis (Wegener Granulomatosis) with Unusual Presentation. (28260778)
2017
4
Healing of leg ulcers associated with granulomatosis with polyangiitis (Wegener granulomatosis) after rituximab therapy. (28207017)
2017
5
Malignant Pyoderma Associated with Granulomatosis with Polyangiitis (Wegener Granulomatosis) as a Unique Indication for Facial Vascularized Composite Allotransplantation: Part I. (27219252)
2016
6
Granulomatous polyangitis (Wegener granulomatosis): Clinical findings and results of long-term follow-up. (28393729)
2016
7
Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. (27521731)
2016
8
Orbital involvement as the initial presentation of Wegener granulomatosis in a 9-year-old girl: MR imaging findings. (27425807)
2016
9
Management Scheme for Cerebral Wegener Granulomatosis: An Unusual Pseudotumoral Skull Base Pathology. (27671887)
2016
10
Monoclonal B-cell Lymphocytosis in a Patient with Wegener Granulomatosis: A Case Report and Update on 2016 World Health Organization Classification. (27625103)
2016
11
Tracheal Stenosis Because of Wegener Granulomatosis Misdiagnosed as Asthma. (27075424)
2016
12
Image Gallery: Symmetrical necrosis of the breast as an inaugural manifestation of granulomatosis with polyangiitis (Wegener granulomatosis). (27790680)
2016
13
Wegener Granulomatosis: Otologic Manifestation as First Symptom. (26157503)
2015
14
Wegener granulomatosis as possible cause of vertigo: case report and review. (26513951)
2015
15
Renal cell carcinoma metastatic to the orbit in a patient with Wegener granulomatosis. (25295684)
2015
16
Nasal mucosa narrow band imaging in granulomatosis with polyangiitis (Wegener granulomatosis): A preliminary study. (25781561)
2015
17
Airway Surgery in Tracheostomised Patients with Wegener Granulomatosis Leading to Subglottic Stenosis. (27366530)
2015
18
Total nasal skeletal reconstruction disfigured by granulomatosis with polyangitis (wegener granulomatosis). (25750847)
2015
19
Wegener granulomatosis with supraglottic involvement. (26433716)
2015
20
Wegener granulomatosis-associated optic perineuritis. (24144064)
2014
21
Long-term Outcome of Airway Stenosis in Granulomatosis With Polyangiitis (Wegener Granulomatosis): An Observational Study. (25321076)
2014
22
Changes in sinonasal mucosa in Wegener granulomatosis. (24616132)
2014
23
Limited-Form Wegener Granulomatosis Case: Anaesthetic Approach and Literature Review. (27366454)
2014
24
Coexistent pulmonary granulomatosis with polyangiitis (Wegener granulomatosis) and Crohn disease. (24525506)
2014
25
Orbital granulomatosis with polyangiitis (Wegener granulomatosis): clinical and pathologic findings. (25076302)
2014
26
An unusual orbital localization of wegener granulomatosis detected by 18F-FDG PET/CT. (23856831)
2014
27
Ultrasonographic imaging of the peripheral nerves in a Wegener granulomatosis patient with multiple mononeuropathies. (24811470)
2014
28
Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis). (23385856)
2013
29
Granulomatosis with polyangiitis (Wegener granulomatosis) as a differential diagnosis of sternal osteomyelitis: the challenges in diagnosis. (24263148)
2013
30
Clinical features and outcomes of 37 Argentinean patients with severe granulomatosis with polyangiitis (wegener granulomatosis). (23364664)
2013
31
Pyoderma gangrenosum and Wegener granulomatosis-like syndrome induced by cocaine. (24252079)
2013
32
Pathology quiz case 3: Wegener granulomatosis. (23681045)
2013
33
Wegener granulomatosis as an uncommon cause of panhypopituitarism in childhood. (23729544)
2013
34
Kidney involvement in a Wegener granulomatosis case. (23897571)
2012
35
Palpable purpura, gingival ulcerations and joint pain in a 24-year-old man. Granulomatosis with polyangiitis (formerly known as Wegener granulomatosis). (22726723)
2012
36
Wegener granulomatosis--rare case presentation. (23777030)
2012
37
Wegener granulomatosis presenting as refractory otitis media: a case report. (22991991)
2012
38
Early extracorporeal life support as rescue for Wegener granulomatosis with diffuse alveolar hemorrhage and acute respiratory distress syndrome: a case report and literature review. (22158275)
2011
39
Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement. (21674413)
2011
40
Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis). (21947937)
2011
41
Wegener granulomatosis (granulomatosis with polyangiitis): evolving concepts in treatment. (21674414)
2011
42
Granulomatous choroiditis in Wegener granulomatosis. (21482884)
2011
43
EULAR/PRINTO/PRES criteria for Henoch-SchAPnlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. (20388738)
2010
44
EULAR/PRINTO/PRES criteria for Henoch-SchAPnlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. (20413568)
2010
45
Isolated blue toe syndrome as the initial sign of Wegener granulomatosis. (20609674)
2010
46
Mucocutaneous leishmaniasis masquerading as Wegener granulomatosis. (20375822)
2010
47
Wegener granulomatosis presenting as epididymitis. (19376569)
2009
48
A hydrophobic patch on proteinase 3, the target of autoantibodies in Wegener granulomatosis, mediates membrane binding via NB1 receptors. (18854317)
2008
49
Labyrinthitis related to Wegener granulomatosis: magnetic resonance imaging findings. (18097336)
2008
50
Mononeuritis multiplex as a presenting feature of Wegener granulomatosis: a case report. (17115101)
2007

Variations for Wegener Granulomatosis

About this section

Copy number variations for Wegener Granulomatosis from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1216291159859611159867782Copy numberFCGR3BWegener''s granulomatosis
2217951161592989161601158Copy numberFCGR3BWegener''s granulomatosis

Expression for genes affiliated with Wegener Granulomatosis

About this section
Search GEO for disease gene expression data for Wegener Granulomatosis.

Pathways for genes affiliated with Wegener Granulomatosis

About this section

Pathways related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

(show all 31)
idSuper pathwaysScoreTop Affiliating Genes
110.0ELANE, MPO, PRTN3
210.0ELANE, MPO, TNF
310.0ELANE, ELN, SELE
49.9CTLA4, IL10, TNF
59.9CXCL8, IFNG, SELE
69.9CXCL8, IFNG, SELE
79.8CRP, CXCL8, TNF
89.8IFNG, IL10, TNF
99.8IFNG, IL10, TNF
10
Show member pathways
9.8IFNG, IL10, TNF
119.8IFNG, IL10, TNF
129.8CXCL8, IL10, TNF
139.8CXCL8, ELANE, MPO, RXRB
14
Show member pathways
9.7CRP, IFNG, MPO, TNF
15
Show member pathways
9.7CTLA4, CXCL8, IFNG, TNF
169.7CXCL8, ELN, SERPINA1, TNF
179.7HLA-DPB1, IFNG, IL10, TNF
189.7IFNG, IL10, MPO, TNF
19
Show member pathways
9.7CXCL8, IFNG, SELE, TNF
209.6IFNG, IL10, SELE, TNF
219.6CCR5, CXCL8, IL10, TNF
22
Show member pathways
9.6CXCL8, IFNG, IL10, TNF
239.6CTLA4, CXCL8, HLA-DPB1, IFNG, TNF
24
Show member pathways
9.5HLA-DPB1, IFNG, IL10, RXRB, TNF
25
Show member pathways
9.5CCR5, CTLA4, IFNG, IL10, TNF
26
Show member pathways
9.5CCR5, HLA-DPB1, IFNG, IL10, TNF
279.4CTSG, CXCL8, IFNG, IL10, TNF
289.4CXCL8, IFNG, IL10, SELE, TNF
299.4CTLA4, IFNG, IL10, MPO, PTPN22, TNF
30
Show member pathways
9.3CTLA4, CXCL8, HLA-DPB1, IFNG, IL10, TNF
31
Show member pathways
7.8CCR5, CD177, CRP, CTLA4, CTSG, CXCL8

GO Terms for genes affiliated with Wegener Granulomatosis

About this section

Cellular components related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1azurophil granule lumenGO:003557810.7CTSG, ELANE, MPO, PRTN3
2external side of plasma membraneGO:000989710.5CCR5, CTLA4, IFNG, TNF
3secretory granuleGO:003014110.0CTSG, ELANE, MPO
4extracellular regionGO:00055769.2CRP, CTSG, CXCL8, ELANE, ELN, IFNG
5extracellular spaceGO:00056159.0CRP, CTSG, CXCL8, ELANE, IFNG, IL10

Biological processes related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1leukocyte migration involved in inflammatory responseGO:000252310.8ELANE, SELE
2antimicrobial humoral responseGO:001973010.8CTSG, ELANE, PRTN3
3endothelial cell apoptotic processGO:007257710.8IL10, TNF
4defense response to fungusGO:005083210.8CTSG, ELANE, MPO
5negative regulation of lipid storageGO:001088810.8CRP, TNF
6positive regulation of immune responseGO:005077810.8CTSG, ELANE
7negative regulation of cytokine secretion involved in immune responseGO:000274010.7IL10, TNF
8positive regulation of interleukin-8 biosynthetic processGO:004541610.7ELANE, TNF
9extracellular matrix disassemblyGO:002261710.7CTSG, ELANE, ELN
10positive regulation of calcidiol 1-monooxygenase activityGO:006055910.7IFNG, TNF
11positive regulation of chemokine biosynthetic processGO:004508010.7IFNG, TNF
12defense response to Gram-positive bacteriumGO:005083010.7CRP, CTSG, TNF
13positive regulation of vitamin D biosynthetic processGO:006055710.7IFNG, TNF
14positive regulation of heterotypic cell-cell adhesionGO:003411610.6IL10, TNF
15receptor biosynthetic processGO:003280010.6IL10, TNF
16calcium-mediated signalingGO:001972210.6CCR5, CXCL8, SELE
17positive regulation of MHC class II biosynthetic processGO:004534810.6IFNG, IL10
18leukocyte migrationGO:005090010.5CD177, ELANE, SELE, TNF
19response to molecule of bacterial originGO:000223710.2CXCL8, IL10
20response to yeastGO:000187810.2ELANE, MPO
21neutrophil degranulationGO:004331210.2CD177, CTSG, ELANE, MPO, PRTN3, SERPINA1
22defense response to bacteriumGO:004274210.1CTSG, ELANE, IFNG, IL10, MPO, TNF
23negative regulation of growth of symbiont in hostGO:004413010.0CTSG, ELANE, IFNG, IL10, MPO, TNF
24cellular response to lipopolysaccharideGO:007122210.0CCR5, CTSG, CXCL8, IFNG, IL10, TNF
25inflammatory responseGO:00069549.9CCR5, CRP, CXCL8, IL10, SELE, TNF
26response to lipopolysaccharideGO:00324969.8CTSG, ELANE, IL10, MPO, PTPN22, SELE
27immune responseGO:00069559.7CCR5, CTLA4, CTSG, CXCL8, HLA-DPB1, IFNG

Molecular functions related to Wegener Granulomatosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytokine activityGO:00051259.6CXCL8, IFNG, IL10, TNF

Sources for Wegener Granulomatosis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet